Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs

Design Therapeutics, Inc.

2024-Q1 EPS reported -$0.20

Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.
Cash and securities $270.7M as of March 31, 2024; expected funding into 2029.
DT-216P2 for Friedreich Ataxia: GLP studies by year-end 2024; patient trials start 2025.
DT-168 for FECD: Phase 1 development expected to start in 2024; observational study enrolling 200 patients.
GeneTAC pipeline: HD and DM1 programs advancing toward development candidates; preclinical data showed mutant gene knockdown.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Design Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $11.1 million.

Period: the quarter ended March 31, 2024
Net income: $11.1 million
Result: reported results

Exact text from the filing

Net loss was $11.1 million for the quarter ended March 31, 2024.

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.